GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » Capex-to-Operating-Cash-Flow

Chiasma (Chiasma) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2021)


View and export this data going back to 2015. Start your Free Trial

What is Chiasma Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Chiasma's Capital Expenditure for the three months ended in Mar. 2021 was $-0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2021 was $-20.64 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Chiasma Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Chiasma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiasma Capex-to-Operating-Cash-Flow Chart

Chiasma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Chiasma Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chiasma's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Chiasma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiasma's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiasma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Chiasma's Capex-to-Operating-Cash-Flow falls into.



Chiasma Capex-to-Operating-Cash-Flow Calculation

Chiasma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2020 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.372) / -75.326
=N/A

Chiasma's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2021 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.004) / -20.644
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiasma  (NAS:CHMA) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Chiasma Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Chiasma's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiasma (Chiasma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
140 Kendrick Street, Building C East, Needham, MA, USA, 02494
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Executives
Roni Mamluk director CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack director THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman director C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick director C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan officer: EVP, Chief Commerical Officer C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere officer: General Counsel C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam officer: See Remarks C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait officer: VP, Fin & Admin, PAO C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick officer: President 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

Chiasma (Chiasma) Headlines

From GuruFocus

Chiasma to Report Fourth Quarter 2020 Results on March 4

By Marketwired Marketwired 02-25-2021

Chiasma to Report First Quarter Financial Results on May 6, 2021

By Marketwired Marketwired 04-29-2021